Topic | Median | Mean | Priority | |
---|---|---|---|---|
 | Accepted as priorities |  |  |  |
 | Quality |  |  |  |
Q 16 | Not using inhaled corticosteroids in patients with uncontrolled asthma | 8 | 8.0 | ++ |
Q 15 | Not using oral anticoagulants in patients with AF and high risk of stroke | 8 | 7.9 | ++ |
Q 11 | Not using ACEIs or ARBs in patients with a history of chronic heart failure | 8 | 7.9 | ++ |
Q 14 | Not using thrombo-embolic prophylaxis in AF patients at low/moderate risk of stroke | 8 | 7.7 | ++ |
Q 5 | Not using ACEIs or ARBs in patients with DM and renal complications | 8 | 7.7 | ++ |
Q 12 | Not using beta blockers in patients with a history of chronic heart failure | 8 | 7.7 | ++ |
Q 4 | Not using metformin as first line antidiabetic in overweight type 2 diabetics | 8 | 7.6 | ++ |
Q 8 | Not using antiplatelets in patients at risk of vascular events | 7 | 7.5 | + |
Q 6 | Not using statins in patients at high risk of cardiovascular events | 7 | 7.4 | + |
Q 17 | Not using bone sparing agents in female patients at high risk of fractures | 7 | 7.3 | + |
Q 3 | Low intensity antidiabetic treatment despite suboptimal HbA1c control | 7 | 7.2 | + |
Q 10 | Not using ACEIs or ARBs in patients with a history of ACS | 7 | 7.0 | + |
Q 2 | Low intensity antihypertensive treatment despite suboptimal BP control | 7 | 6.9 | + |
Q 9 | Not using beta blockers in coronary heart disease | 7 | 6.8 | + |
Q 7 | Underdosing of statins in patients at high risk of cardiovascular events | 7 | 6.7 | + |
 | Safety |  |  |  |
S 20 | Using MTX without taking precautionary action to prevent patient overdosing | 9 | 8.4 | ++ |
S 1 | Not using gastro-protection in oral NSAIDs/antiplatelets users at high risk of bleeding | 8 | 8.2 | ++ |
S 3 | Using oral NSAIDs in patients at increased risk of renal failure | 8 | 7.9 | ++ |
S 21 | Inconsistent monitoring of FBC in patients on DMARDs | 8 | 7.8 | ++ |
S 27 | Using sedatives, antipsychotics, anticholinergics in elderly patients | 7 | 7.3 | + |
S 19 | Using bone protection in users of long term oral corticosteroids | 7 | 7.3 | + |
S 23 | Excess duration of female hormones in patients at risk of gynaecological cancer | 7 | 7.3 | + |
S 10 | Excess duration of potassium supplements and potassium sparing diuretics | 7 | 7.2 | + |
S 28 | Using drugs to avoid in patients with heart failure | 7 | 7.1 | + |
S 18 | Excessive dosing of digoxin in patients susceptible to digoxin toxicity | 7 | 7.1 | + |
S 24 | Inconsistent monitoring of thyroid function in patients prescribed amiodarone | 7 | 7.0 | + |
S 6 | Inconsistent monitoring of U&Es in patients at risk of electrolyte imbalance | 7 | 7.0 | + |
S 14 | Co-prescribing beta blockers and rate-limiting calcium channel blockers | 7 | 6.9 | + |
S 25 | Using theophylline in elderly COPD patients without a compelling indication | 7 | 6.9 | + |
S 15 | Using beta blockers in patients with active asthma | 7 | 6.8 | + |
S 13 | Not using of laxatives in strong opioid users | 7 | 6.8 | + |
S 29 | Using drugs to avoid in children and young adults | 7 | 6.7 | + |
S 5 | Using COX II inhibitors in patients at high risk of cardiovascular events | 7 | 6.6 | + |
S 7 | Using thiazide diuretics in patients with a history of CKD | 7 | 6.6 | + |
S 17 | Using long acting sulphonylureas in patients at risk of hypoglycaemia | 7 | 6.6 | + |
S 4 | Using COX II inhibitors without compelling indication (low dose aspirin users) | 7 | 6.4 | + |
S 16 | Using metformin in patients with CKD | 7 | 6.4 | + |
S 26 | Excessive dosing of statins in patients on interacting drugs | 7 | 6.3 | + |
 | Not scored as priorities for medication improvement |  |  |  |
 | Quality |  |  |  |
Q 13 | Inadequate dose titration of ACEI, ARBs and BBs in chronic heart failure | 6 | 6.2 | Â |
Q 1 | Not using first line antihypertensives when initiating treatment for high blood pressure | 6 | 6.4 | Â |
Q 18 | Not using calcium/vitamin D supplementation in female elderly patients | 6 | 6.4 | Â |
 | Safety |  |  |  |
S 2 | Using oral NSAIDs in the elderly without compelling indication (no previous trial of full dose paracetamol) | 6 | 6.6 | Â |
S 9 | Using of aldosterone antagonists in patients with a history of CKD | 6 | 6.5 | Â |
S 11 | Co-prescribing anti-infectives with high risk of affecting INR in patients on warfarin | 6 | 6.4 | Â |
S 12 | Using warfarin without a compelling indication in AF with low risk of stroke | 6 | 6.3 | Â |
S 22 | Using HRT in female patients at high risk of cardiovascular events | 6 | 6.2 | Â |
S 8 | Not using allopurinol in thiazide users with a history of gout | 6 | 5.8 | Â |